26.67
0.42%
0.27
Schlusskurs vom Vortag:
$26.40
Offen:
$26.6
24-Stunden-Volumen:
74,719
Relative Volume:
0.07
Marktkapitalisierung:
$1.75B
Einnahmen:
$8.30M
Nettoeinkommen (Verlust:
$-150.22M
KGV:
-10.10
EPS:
-2.64
Netto-Cashflow:
$-122.93M
1W Leistung:
+2.99%
1M Leistung:
-7.60%
6M Leistung:
-29.63%
1J Leistung:
-5.36%
Celldex Therapeutics Inc Stock (CLDX) Company Profile
Firmenname
Celldex Therapeutics Inc
Sektor
Branche
Telefon
908-200-7500
Adresse
53 FRONTAGE ROAD, HAMPTON
Vergleichen Sie CLDX mit anderen Aktien
Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
---|---|---|---|---|---|---|
CLDX | 26.57 | 1.75B | 8.30M | -150.22M | -122.93M | -2.64 |
VRTX | 447.21 | 115.74B | 10.63B | -479.80M | -1.35B | 13.33 |
REGN | 737.75 | 81.65B | 13.85B | 4.65B | 3.32B | 35.06 |
ARGX | 586.52 | 34.86B | 1.86B | -40.29M | -1.28B | -4.16 |
ALNY | 248.92 | 32.09B | 2.09B | -332.26M | 16.06M | -4.14 |
BNTX | 102.55 | 24.49B | 3.30B | -501.07M | 1.03B | 11.54 |
Celldex Therapeutics Inc Stock (CLDX) Upgrades & Downgrades
Datum | Aktion | Analytiker | Ratingänderung |
---|---|---|---|
2024-10-07 | Eingeleitet | Citigroup | Buy |
2024-09-30 | Eingeleitet | Goldman | Neutral |
2024-09-27 | Herabstufung | Wolfe Research | Outperform → Peer Perform |
2024-06-18 | Eingeleitet | Stifel | Buy |
2024-06-11 | Eingeleitet | Wolfe Research | Outperform |
2023-12-20 | Eingeleitet | TD Cowen | Outperform |
2023-11-10 | Hochstufung | Wells Fargo | Underweight → Equal Weight |
2023-08-22 | Eingeleitet | Wells Fargo | Underweight |
2021-09-17 | Eingeleitet | Jefferies | Buy |
2021-09-10 | Eingeleitet | SVB Leerink | Outperform |
2021-07-22 | Eingeleitet | Guggenheim | Buy |
2020-02-21 | Eingeleitet | Cantor Fitzgerald | Overweight |
2017-08-01 | Fortgesetzt | H.C. Wainwright | Buy |
2016-11-07 | Eingeleitet | Aegis Capital | Buy |
2016-03-08 | Herabstufung | Jefferies | Buy → Hold |
2016-03-07 | Herabstufung | Guggenheim | Buy → Neutral |
2016-03-07 | Herabstufung | Leerink Partners | Outperform → Mkt Perform |
2016-03-07 | Herabstufung | Wedbush | Outperform → Neutral |
2016-03-01 | Eingeleitet | H.C. Wainwright | Buy |
2015-08-11 | Bestätigt | Brean Capital | Buy |
2015-08-11 | Bestätigt | Oppenheimer | Outperform |
2015-08-11 | Bestätigt | ROTH Capital | Buy |
2015-06-02 | Bestätigt | WBB Securities | Strong Buy |
2014-11-17 | Bestätigt | ROTH Capital | Buy |
2014-03-04 | Bestätigt | Oppenheimer | Outperform |
2013-07-08 | Bestätigt | Cantor Fitzgerald | Buy |
2013-03-08 | Bestätigt | Cantor Fitzgerald | Buy |
2013-02-26 | Bestätigt | Oppenheimer | Outperform |
2013-01-10 | Bestätigt | Cantor Fitzgerald | Buy |
2012-10-02 | Bestätigt | Oppenheimer | Outperform |
2012-09-14 | Bestätigt | Cantor Fitzgerald | Buy |
Alle ansehen
Celldex Therapeutics Inc Aktie (CLDX) Neueste Nachrichten
Insider Spends US$308k Buying More Shares In Celldex Therapeutics - Simply Wall St
Celldex Therapeutics (NASDAQ:CLDX) Given Buy Rating at HC Wainwright - MarketBeat
Celldex Announces First Patient Dosed in Phase 1 Healthy Volunteer Study of CDX-622, a Bispecific Antibody, for the Treatment of Inflammatory Diseases - The Manila Times
Celldex Launches Phase 1 Trial of Novel Dual-Action Inflammatory Disease Treatment | CLDX Stock News - StockTitan
Beyond The Numbers: 11 Analysts Discuss Celldex Therapeutics Stock - Benzinga
Celldex Therapeutics Reports Q3 2024 Progress and Financials - TipRanks
Celldex Therapeutics (NASDAQ:CLDX) Sets New 12-Month LowWhat's Next? - MarketBeat
Celldex stock touches 52-week low at $24.41 amid market shifts - Investing.com Canada
Steven Cohen's Strategic Reduction in Celldex Therapeutics Holdi - GuruFocus.com
Eventide Asset Management's Strategic Acquisition in Celldex The - GuruFocus.com
Celldex Therapeutics' SWOT analysis: barzolvolimab stock potential in urticaria treatment - Investing.com India
Polar Capital Holdings Plc Reduces Stake in Celldex Therapeutics Inc - GuruFocus.com
Insider Buying: Celldex Therapeutics Inc (CLDX) President & CEO Acquires Shares - GuruFocus.com
Celldex Therapeutics (NASDAQ:CLDX) Trading 4.2% Higher Following Insider Buying Activity - Defense World
FMR LLC's Strategic Reduction in Celldex Therapeutics Inc Shares - GuruFocus.com
Insider Buying: Celldex Therapeutics, Inc. (NASDAQ:CLDX) CEO Buys 11,500 Shares of Stock - MarketBeat
Celldex Therapeutics CEO Anthony Marucci buys $308,430 in stock By Investing.com - Investing.com UK
Celldex Therapeutics to Present at Upcoming Investor Conferences - The Manila Times
Celldex (CLDX) to Present at Two Major Healthcare Investor Conferences in Q4 | CLDX Stock News - StockTitan
Leerink Partnrs Analysts Lower Earnings Estimates for CLDX - MarketBeat
What is HC Wainwright's Estimate for CLDX FY2024 Earnings? - MarketBeat
HC Wainwright Reiterates “Buy” Rating for Celldex Therapeutics (NASDAQ:CLDX) - Defense World
Wellington Management Group LLP's Strategic Acquisition in Celld - GuruFocus.com
FY2028 Earnings Forecast for CLDX Issued By Leerink Partnrs - MarketBeat
Celldex Therapeutics Third Quarter 2024 Earnings: Beats Expectations - Simply Wall St
Celldex Therapeutics, Inc. (NASDAQ:CLDX) Receives Consensus Rating of "Moderate Buy" from Brokerages - MarketBeat
Celldex Therapeutics (CLDX) Reports Q3 Loss, Tops Revenue Estimates - Yahoo Finance
Celldex: Q3 Earnings Snapshot - San Antonio Express-News
Celldex Reports Third Quarter 2024 Financial Results and Provides Corporate Update - The Manila Times
Celldex Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 - Marketscreener.com
Celldex stock touches 52-week low at $25.04 amid market shifts By Investing.com - Investing.com South Africa
Celldex Therapeutics (NASDAQ:CLDX) Reaches New 12-Month LowTime to Sell? - MarketBeat
Celldex stock touches 52-week low at $25.04 amid market shifts - Investing.com India
Celldex Therapeutics' Strong Cash Runway Supports Barzolvolimab's Path To Market - Seeking Alpha
Urticaria Clinical Trial Pipeline Accelerates: 20+ Leading Companies Pioneering New Treatments | DelveInsight - GlobeNewswire
Urticaria Clinical Trial Pipeline Accelerates: 20+ Leading Companies Pioneering New Treatments | DelveInsight - GlobeNewswire Inc.
Emerald Advisers LLC Has $15.51 Million Holdings in Celldex Therapeutics, Inc. (NASDAQ:CLDX) - MarketBeat
Evommune raises $115M to accelerate immune drug tests - Yahoo Finance
Market reaction to Intellia data suggests perfection remains bar for gene editing - BioCentury
Celldex Therapeutics (NASDAQ:CLDX) Trading Down 6%What's Next? - MarketBeat
Prurigo Nodularis Pipeline Update 2024: FDA Approvals, - openPR
Celldex shares hold as analyst maintains Buy rating By Investing.com - Investing.com UK
Celldex selloff creates buying opportunity, says Guggenheim - Yahoo Finance
Celldex shares gain as TD Cowen affirms Buy rating on robust Ph2 data - Investing.com UK
Analyst Expectations For Celldex Therapeutics's Future - Benzinga
HC Wainwright Reaffirms "Buy" Rating for Celldex Therapeutics (NASDAQ:CLDX) - MarketBeat
Celldex Therapeutics' SWOT analysis: barzolvolimab stock potential in urticaria - Investing.com India
Celldex Therapeutics (NASDAQ:CLDX) pulls back 6.1% this week, but still delivers shareholders fantastic 57% CAGR over 5 years - Yahoo Finance
Novo Holdings A S Grows Stock Position in Celldex Therapeutics, Inc. (NASDAQ:CLDX) - MarketBeat
Celldex Announces Barzolvolimab Met All Primary and Secondary Endpoints with High Statistical Significance in Positive Phase 2 Study in Chronic Inducible Urticaria - ForexTV.com
Finanzdaten der Celldex Therapeutics Inc-Aktie (CLDX)
Umsatz
Nettogewinn
Free Cashflow
ENV
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):